Overview

Open-label Study With Bosentan in Interstitial Lung Disease

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Actelion
Treatments:
Bosentan